Motzer RJ, Penkov K, Haanen JBAG, et al. JAVELIN Renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC). ESMO 2018, abstract LBA6_PR.
Apatinib versus placebo bij radioactief jodium-refractair gedifferentieerd schildkliercarcinoom
mei 2022 | Hoofd-halsoncologie